French devicemaker Quantel Medical said Wednesday it has received FDA 510(k) clearance for the Optimis Fusion integrated laser platform for the treatment of cataract and glaucoma.

The platform, currently available throughout the U.S., allows ophthalmologists to treat both eye ailments with one combination system, incorporating advanced selective laser trabeculoplasty, photoregeneration therapy and traditional YAG photodisruption treatments, the company says.

According to Quantel, SLT targets melanin-rich cells that absorb laser energy, promoting healing and improving the functioning of tissue in the wall of the eye that drain fluid from the eye.  There procedure carries no risk of thermal damage and can safely be repeated, the company adds.

The YAG mode delivers high-performance photodisruption for capsulotomy and peripheral iridotomy surgical procedures, Quantel notes, adding that the two-point laser beam enables fast and accurate targeting of the capsule.

The device is also available throughout Europe and Asia. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.